Can the 21-gene recurrence score (RS) assay spare some patients from unnecessary adjuvant chemotherapy in hormone–receptor-positive, HER2 negative early breast cancer with low burden axillary disease. Issue 2 (February 2022) - Barron, Marina; Asaad, Amira; Idaewor, Philip; Rasheed, Noreen; Abdalla Al-Zawi, Abdalla Saad